Health Risk Assessment Practices in the U.S. Food and Drug Administration

Author： Gaylor D.W.   Axelrad J.A.   Brown R.P.   Cavagnaro J.A.   Cyr W.H.   Hulebak K.L.   Lorentzen R.J.   Miller M.A.   Mulligan L.T.   Schwetz B.A.  

Publisher： Academic Press

ISSN： 0273-2300

Source： Regulatory Toxicology and Pharmacology, Vol.26, Iss.3, 1997-12, pp. : 307-321

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Policy and Health Implications of Using the U.S. Food and Drug Administration Product Design Approach in Reducing Tobacco Product Risk

By  

Current Drug Abuse Reviews, Vol. 1, Iss. 2, 2008-06 ,pp. : 135-141

Bentham Science Publishers

Access to resources Recommend Favorite

Auflistung der U.S. Food and Drug Administration: Pharmacogenomic Biomarkers in Drug Labels

By  

PHARMAKON, Vol. 1, Iss. 1, 2013-01 ,pp. : 36-39

Govi-Verlag

Access to resources Recommend Favorite

The US Food and Drug Administration and Emergency Contraception

By Fox Anthony W.  

International Journal of Pharmaceutical Medicine, Vol. 19, Iss. 3, 2005-01 ,pp. : 139-140

Adis International

Access to resources Recommend Favorite

Scientific Issues in the U.S. EPA Framework for Metals Risk Assessment

By Bradham Karen   Wentsel Randall  

Journal of Toxicology and Environmental Health, Vol. 73, Iss. 2-3, 2010-01 ,pp. : 108-113

Taylor & Francis Ltd

Access to resources Recommend Favorite

US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids: Pros and Cons, and a European Perspective

By Mercadante Sebastiano  

Drugs, Vol. 72, Iss. 18, 2012-12 ,pp. : 2327-2332

Adis International

Access to resources Recommend Favorite